nVerses Capital’s Coherus Oncology CHRS Stock Holding History

nVerses Capital’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-4,500	Closed	-$7.79K	–	1054
2024 Q2	$7.79K	Buy	+4,500	New	+$9.06K	﹤0.01%	927

Other funds holding CHRS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

nVerses Capital's CHRS Position: Q3 2024 in Review

nVerses Capital sold out of Coherus Oncology (CHRS) in Q3 2024, closing a stake of 4,500 shares — an estimated $7.79K sold.

nVerses Capital first reported a position in CHRS in Q2 2024 and held it in 1 quarter. The position peaked at $7.79K in Q2 2024. 128 funds tracked by Wall St. Rank hold CHRS as of Q3 2024.

nVerses Capital reported no remaining Coherus Oncology position as of Q3 2024 after selling out during the quarter.
nVerses Capital sold 4,500 Coherus Oncology shares in Q3 2024, an estimated $7.79K.
nVerses Capital first reported a position in Coherus Oncology in Q2 2024 and held it in 1 quarter.
nVerses Capital's Coherus Oncology position peaked at $7.79K in Q2 2024.
128 funds tracked by Wall St. Rank held Coherus Oncology as of Q3 2024.

Based on nVerses Capital's 13F filing for Q3 2024, filed 16 Oct 2024.